RGC Stock Analysis: Buy, Sell, or Hold?
RGC - Regencell Bioscience Holdings Limited Ordinary Shares
$23.33
-2.34 (-9.12%)
▼
5d:
-7.48%
30d:
-11.06%
90d:
+10.26%
HOLD
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: Jun 02, 2026
Smart Money Distribution
RGC is up 8.2% this week, but smart money is buying puts. Top strike: $25 2026-06-18 with 28 OI. Put ratio: 95% View Scanner →
Strength: 8.6/10
Get Alerted When RGC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: RGC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: RGC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: RGC is currently trading at $23.33, which is considered oversold relative to its 30-day fair value range of $23.64 to $26.74.
Technical Outlook: Technically, RGC is in a uptrend. Immediate support is located at $22.35, while resistance sits at $29.50. Short-term momentum is weak, with the stock down 9.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (19th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RGC is in a uptrend. Immediate support is located at $22.35, while resistance sits at $29.50. Short-term momentum is weak, with the stock down 9.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (19th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$23.64 -
$26.74
Company Quality Score
49/100
(HOLD)
Options IV Signal
19th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
80.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 19th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-9.1%)
- CAUTION: Recommendation downgraded due to -7.5% 5-day decline
Fair Price Analysis
30-Day Fair Range
$23.64 -
$26.74
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$4.62
(19.8%)
Support & Resistance Levels
Support Level
$22.35
Resistance Level
$29.50
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Share & Embed Analysis
Last updated: March 31, 2026 8:39 AM ET
Data refreshes hourly during market hours. Next update: 9:39 AM
Data refreshes hourly during market hours. Next update: 9:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RGC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 55 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 63 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 56 HOLD |
